Skip to main content
Contact CVRx Contact CVRx

Rebalance the autonomic nervous system.
Improve heart failure symptoms.

illustration of barostim's baroreflex activation therapy device connecting to the heart and to the brain

Barostim is an option to improve exercise capacity in the 70% of patients not indicated for CRT

GDMT improves heart failure mortality and morbidity in HFrEF patients, but only shows modest improvement in exercise capacity.1

1. Lewis G et al. Circ Heart Fail. 2022 May; 15(5):510-524;
2. Abraham WT, Zile MR et al. JACC: Heart Failure 2015 June; 3(6):487-496;
3. Zile MR, et al. J Am Coll Cardiol 2020; 76:1-13;
4. Heidenreich PA, et al. 2022 Circulation. 2022;145:e895–e1032; Class I and Class IIa recommendations

Barostim rebalances the autonomic nervous system

Barostim works by electrically stimulating carotid baroreceptors which increases baroreflex sensitivity, rebalances the autonomic nervous system and improves heart failure symptoms.

Watch the animation
barostim's baroreflex activation therapy device doodle barostim's baroreflex activation therapy device

The Barostim System

Baroreflex Activation Therapy is delivered by the Barostim NEO2, an implantable pulse generator (IPG) designed to deliver continuous electrical stimulation to carotid baroreceptors.

The Barostim System comprises the Barostim NEO2 IPG, the Carotid Sinus Lead and a simple, intuitive Programmer.

Barostim™ Therapy Illustration

Safe implant procedure

The Barostim System is implanted in a safe surgical procedure where the Carotid Sinus Lead is sutured to the carotid sinus and the Barostim NEO2 IPG is inserted in a standard device pocket.

Procedures are typically performed on an outpatient basis.

The system contains no hardware in the heart or vasculature.

Learn about the results of the pivotal BeAT-HF trial